

February 10, 2022  
Symbio Pharmaceuticals Limited  
Fuminori Yoshida  
Representative Director  
President and Chief Executive Officer  
(Securities Code: 4582)

**Notice regarding difference between earnings forecast and  
the actual results for the fiscal year ended December 31, 2021**

TOKYO, Japan, February 10, 2022 -- Symbio Pharmaceuticals Limited (Headquarters: Tokyo, "Symbio" or the "Company") today announced a difference between the Company's earnings forecast and actual results for fiscal year ended December 31, 2021, as below. The actual results were announced earlier today in the Company's "Summary of Financial Statements for the Fiscal Year Ended December 31, 2021 [Japanese GAAP] (Non-consolidated)."

1. Difference between earnings forecast and actual results for the fiscal year ended December 31, 2021 (January 1, 2021 to December 31, 2021)

	Net Sales	Operating Profit (Loss)	Ordinary Profit (Loss)	Net Profit (Loss)	Earnings per share
	Yen millions	Yen millions	Yen millions	Yen millions	Yen
Forecast (A)	9,151	1,361	1,350	1,149	29.99
Actual (B)	8,256	1,016	1,001	2,032	53.04
Difference (B-A)	(894)	(344)	(348)	883	—
Percentage Change (%)	(9.8)	(25.3)	(25.8)	76.9	—
[Reference] Prior Year Results (FY 2020)	2,987	(4,506)	(4,615)	(4,090)	(124.13)

2. Reasons for difference

The difference between forecasted and actual Net Sales is due to (1) the negative impact of the sale of residual inventory of TREAKISYM® freeze-dried (FD) formulation in the market sold to Eisai before December 2020, (2) the continued impact of COVID-19, which resulted in postponed medical treatments as well as constrained sales activities due to restrictions on visits to facilities.

In addition, a 331 million yen inventory loss of TREAKISYM® FD formulation was recorded under cost of sales. The inventory loss was primarily a result of the rapid progress in conversion from FD to TREAKISYM® ready-to-dilute (RTD) formulation. Notwithstanding these factors, the Company was

able to post operating income of 1,016 million yen and ordinary income of 1,001 million yen, largely driven by our transition to in-house sales of TREAKISYM®.

### 3. Recording of income taxes—deferred (benefit)

Net income exceeded the forecast of 1,149 million yen by 76.9% due to the recording of 1,275 million yen in deferred tax assets and income taxes-deferred (benefit) as a result of careful assessment of the recoverability of deferred tax assets in light of business results for the fiscal year ending December 31, 2021.

For more information, please refer to the "Summary of Financial Statements for the Fiscal Year Ended December 31, 2021 [Japanese GAAP] (Non-consolidated)" released today (February 10, 2022).

#### **[Contact]**

Investor Relations

Tel: +81(0)3 5472 1125